Skip to main content

Table 1 Patient demographics and disease-specific properties at baseline

From: Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months

 

mITT

(n = 282)

mITTe

(n = 212)

Male

134 (47.5)

102 (48.1)

Age mean (SD)

40.8 (± 13.9)

39.7 (± 12.0)

Marital status

  

Single

116 (41.1)

88 (41.5)

Married/living together

156 (55.3)

117 (55.2)

Divorced

8 (2.8)

7 (3.3)

Widowed

2 (0.7)

-

Stool frequency

  

Normal

33 (11.7)

22 (10.4)

1–2 stools more than normal

44 (15.6)

36 (17.0)

3–4 stools more than normal

94 (33.3)

71 (33.5)

 ≥ 5 stools more than normal

111 (39.4)

83 (39.2)

Rectal bleeding

  

No blood seen

95 (33.7)

68 (32.1)

Streaks of blood with stool less than half the time

80 (28.4)

54 (25.5)

Obvious blood with stool most of the time

82 (29.1)

70 (33.0)

Blood alone passes

25 (8.9)

20 (9.4)

Physician global assessment

  

Normal

8 (2.8)

7 (3.3)

Mild disease

54 (19.1)

39 (18.4)

Moderate disease

172 (61.0)

130 (61.3)

Severe disease

48 (17.0)

36 (17.0)

Alcohol consumption (actual)

  

No

143 (50.7%)

115 (54.2)

Yes

139 (49.3%)

97 (45.8)

Frequency of alcohol consumption (n = 139)

  

Occasional

117 (81.8)

95 (82.6)

Once a week

12 (8.4)

11 (9.6)

Several times a week

9 (6.3)

5 (4.3)

Daily

5 (3.5)

4 (3.5)

Nicotine consumption

  

No

254 (90.1)

189 (89.2)

Yes

28 (9.9)

23 (10.8)

Abuse of other substances

  

No

281 (99.6)

211 (95.5)

Yes (Cannabis)

1 (0.4)

1 (0.5)

  1. Data are shown as n (%), if not stated otherwise. mITT: modified intention to treat analysis set, mITTe: all patients of the mITT who had been employed at baseline